Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

New Delhi, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The global liver fibrosis treatment market was valued at USD 17.51 billion in 2024 and is projected to reach USD 51.16 billion by 2033, growing at a ...

offering comprehensive insights into the Liver Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Liver Fibrosis statistics, highlighting the current and ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

CHICAGO, NY, UNITED STATES, January 21, 2025 /EINPresswire / -- The global liver fibrosis treatment market is set to witness significant expansion over the coming decade, with revenues anticipated ...

Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...